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Abstract: Background: Sarcoma patients often experience a long time to diagnosis, known as the total
interval. This interval can be divided into the patient (time from symptoms to doctor consultation)
and diagnostic intervals (time from first consultation to diagnosis). In other cancers, a long total
interval has been associated with worse outcomes, but its effect on health-related quality of life
(HRQoL) has never been investigated among sarcoma patients. This study investigates the association
between (1) the actual time to diagnosis and HRQoL; (2) the perceived impact of the diagnostic
interval length and HRQoL; (3) the actual length and perceived impact of the length and the HRQoL
of sarcoma survivors. Methods: A cross-sectional study was performed among sarcoma patients aged
≥18, diagnosed 2–10 years ago in the Netherlands. The participants completed a questionnaire on
HRQoL, the time to diagnosis, the perceived impact of the diagnostic interval on HRQoL, and coping.
Results: 1099 participants were included (response rate, 58%). The mean time since diagnosis was
67.4 months. More than half reported a patient (60%) or diagnostic interval (55%) ≥1 month. A third
(31%) perceived a negative impact of the diagnostic interval length on HRQoL. Patient or diagnostic
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interval length was not associated with HRQoL. By contrast, participants perceiving a negative impact
(32%) had lower HRQoL scores than those perceiving a positive (11%) or no impact (58%) (p = 0.000).
This association remained significant in a multivariable model, in which maladaptive coping strategies
and tumour characteristics were also found to be associated with HRQoL. Participants perceiving a
negative impact of the length of the diagnostic interval related this to high psychological distress
levels, more physical disabilities, and worse prognosis. Conclusion: The perceived impact of the
diagnostic interval length was associated with the HRQoL of sarcoma survivors, whereas the actual
length was not associated with HRQoL. Maladaptive coping strategies were independently associated
with HRQoL. This offers opportunities for early intervention to improve HRQoL.
Keywords: time to diagnosis; health-related quality of life; sarcoma; diagnostic interval
1. Introduction
Sarcomas are mesenchymal tumours, with considerable heterogeneity regarding the age of onset,
anatomic location, histological subtype, and outcome. These solid tumours consist of more than 100
histologic subtypes that originate in soft tissue (STS; 80%) or bone (BS; 20%). Sarcomas are typical
examples of rare cancers (affecting fewer than six individuals per 100,000/year) and have an estimated
incidence of 4–5 per 100,000 per year [1]. Patients with rare cancers have worse outcomes than patients
with common cancers: in the Netherlands, the five-year survival rates for all subtypes of STS and
BS taken together are 58% and 49%, respectively, which are lower than the five-year survival rates
for all cancers diagnosed in the Netherlands (65%) [2]. Given the rarity and heterogeneity of the
disease, sarcomas are often not recognized by healthcare providers, leading to delayed diagnostic
pathways. Additionally, the diagnostic process can be complex, leading to a prolonged diagnostic
time in expert centres. Furthermore, a lack of expert pathologists and the absence of tumour-specific
multidisciplinary teams, cancer-specific therapies, and clinical trials often preclude patients with rare
cancer from receiving a proper, timely diagnosis and adequate care [3].
Historically, the evaluation of oncologic care has focused on clinical outcomes, such as
treatment-related toxicities and overall survival. Currently, more attention is being given to
patient-reported outcomes, such as health-related quality of life (HRQoL). HRQoL refers to the
impact of disease and treatment on domains of physical, psychological, and social functioning [4].
In other malignancies, a prolonged time to cancer diagnosis has been associated with worse HRQoL [5].
The association between the time to diagnosis and HRQoL has never been investigated quantitatively
among sarcoma patients, but qualitative reports indicate that the time to diagnosis influences patients’
physical and psychosocial well-being [6,7]. This may not only influence HRQoL in the short-term but
may also influence HRQoL among sarcoma survivors.
Although the survival rates of sarcoma patients lag behind those of common cancer patients,
there are an estimated 280,000 sarcoma survivors in Europe [1] who require supportive and rehabilitation
services. To improve these services, we need to understand the care experiences and needs of sarcoma
survivors. Survivorship care focusses on the health and well-being of a person with cancer from the
time of diagnosis until the end of life [8], including issues related to follow-up care (e.g., regular health
and wellness check-ups), late effects of treatment, cancer recurrence, second cancers, and HRQoL.
This study investigates the association between actual time to diagnosis and HRQoL in a group
of adult sarcoma survivors. Furthermore, the perceived impact of the diagnostic interval length on
HRQoL, both quantitative and qualitative, and the independent association of time to diagnosis and
other variables with HRQoL are investigated.
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2. Methods
2.1. Study Design and Participants
This cross-sectional cohort study included Dutch sarcoma patients aged ≥18, registered in the
Netherlands Cancer Registry (NCR), and diagnosed between 1 January 2008 and 31 December 2016
at one of the participating sarcoma expertise centres (Radboud University Medical Centre Nijmegen,
Antoni van Leeuwenhoek Amsterdam-The Netherlands Cancer Institute, University Medical Centre
Groningen, Leiden University Medical Centre, Erasmus MC Cancer Institute Rotterdam, and Maastricht
University Medical Centre). Participants had to be able to complete Dutch questionnaires by themselves.
Patients with desmoid fibromatosis, grade 1 chondrosarcoma, atypical lipomatous tumours, giant-cell
tumours, or gastro-intestinal stromal tumours were excluded due to their indolent clinical behaviour
or different treatment strategies compared to patients with other sarcomas. Ethical approval was given
by the medical ethical committee of Radboud University Medical Centre (2017-3944), and the study
was registered in the Dutch Trial Registry (NTR-7253).
2.2. Recruitment and Data Collection
Eligible patients received a letter from their (ex-)treating physician explaining the purpose of the
study. After providing informed consent, patients could complete questionnaires either online or by
pencil-and-paper. Further details of this method have been described previously [9,10].
2.3. Study Measures
While this study was primarily designed to examine HRQoL among sarcoma survivors compared
to that in an age- and sex-matched normative population (https://www.trialregister.nl/trial/7048;
NTR-7253, accessed on 24 July 2020), the current study is a preplanned, secondary analysis investigating
the association between time to diagnosis and HRQoL.
2.4. Time to Diagnosis
The time to diagnosis is often referred to as the total interval. The total interval, describing the
time from the first symptom until (histological) diagnosis, can be divided into patient and diagnostic
intervals [6,11,12]. These encompass the time from the first symptom until the first presentation to a
doctor (patient interval), and the time from this first presentation until pathologic diagnosis (diagnostic
interval). The diagnostic interval can be further divided into primary care, secondary care, and tertiary
care intervals.
Questions on patient and diagnostic interval length were designed by the study group, all the
intervals were patient-reported, and the answers were categorical. The meaning of each interval
was explained in detail to the patients to overcome interpretation issues. The study population was
grouped by the length of the patient and diagnostic intervals, with a cut-off point of 1 month, based on
previous literature [13–16]. Many countries deem four weeks or one month for the diagnostic interval as
appropriate, and the Dutch SONCOS guidelines (Stichting ONCologische Samenwerking; foundation
for multidisciplinary oncological collaboration) accepts a period of four weeks between referral by the
GP and histological cancer diagnosis [17].
2.5. Health-Related Quality of Life: EORTC QLQ-C30
HRQoL was measured by the European Organization for Research and Treatment for Cancer
Quality of Life Questionnaire-C30 (EORTC QLQ-C30). This self-administered 30-item questionnaire
has been validated to measure HRQoL in cancer patients [18]. It consists of global quality of life (QoL),
five functional scales, three symptom scales, and several single items assessing additional symptoms
and the perceived financial impact of the disease. The global QoL is the patient’s rating of their overall
health and quality of life during the past week; the functional scales assess physical, cognitive, role,
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social, and emotional functioning. The global QoL and the functioning scales were used in our analyses.
After the linear transformation of the raw scores, all the scores range from 0 to 100; a higher score
represents a better global QoL or level of functioning [19]. Apart from a quantitative score, one can
examine clinical relevance using the guidelines of Cocks et al.; they distinguish four effect sizes: trivial,
small, medium, and large [20]. Each scale has its own threshold between size classes. A guideline
for the interpretation of the clinical impact of emotional functioning is missing; therefore, the cut-off
points of role functioning were used, as this is the most conservative scale and this method has been
described previously [21].
2.6. Perceived Impact of Diagnostic Interval Length on HRQoL
This was assessed by a single question—“Do you think your HRQoL was influenced by your
diagnostic interval length?”—and the option for patients to explain their multiple-choice answer (yes,
negatively; yes, positively; or no) in an open text field.
2.7. Socio-Demographic and Tumour Characteristics
Tumour characteristics were available from the NCR, which routinely collects data of all individuals
newly diagnosed with cancer. These include the date of diagnosis, histology, tumour grade, localisation,
and stage at diagnosis, as well as several patient characteristics such as the age at diagnosis, gender,
and socio-economic status (SES). Patients were grouped into clinically relevant subgroups based on
age (18–39, 40–69, ≥70 years old). SES was derived from zip codes and is based on education, income,
and employment status [22]. The date of participation was subtracted from the date of diagnosis to
calculate the time since diagnosis. The treatment modalities were patient-reported and include all the
treatments patients have had since their primary diagnosis.
2.8. Coping
Coping, the way in which an individual conducts themself to decrease the effect of a stressful
situation [23], was assessed using the Illness Cognition Questionnaire for chronic diseases (ICQ) [24].
This 18-item questionnaire consists of three cognition subscales of six items rated on a 4-point Likert
scale: helplessness as a way of emphasizing the aversive meaning of the disease, acceptance as a
way of diminishing the aversive meaning, and perceived benefits as a way of adding a positive
meaning to the disease [24]. The total subscale scores could range from 6 to 24, with higher scores
on helplessness and lower scores on acceptance and disease benefits indicating maladaptive coping
strategies. Adaptive coping means that one evaluates the situation, actively seeks help, considers all
thinkable solutions, and actively tries to solve the problem, while maladaptive coping means one will
try to move away from the stressful event, indicating that the problem will not be solved.
2.9. Statistical Analyses
Descriptive statistics were used to describe the study population. Categorical variables are
presented as numbers and percentages; for continuous variables, means and standard deviations
are reported.
To investigate the association between the patient and diagnostic interval length, perceived impact
of the length of the diagnostic interval, and HRQoL (global QoL and all five functioning scales), a series
of one-way analysis of variance (ANOVA) tests were conducted, with a cut-off point of 1 month.
The independent association between the interval length, perceived impact of the diagnostic
interval on HRQoL, patient and tumour characteristics, and coping strategies were tested using
multivariable linear regression analyses (for global QoL and all five functioning scales).
Open field answers given by patients who described a negative impact of their diagnostic
interval length on HRQoL were analysed by two investigators (Vicky Soomers and Olga Husson using
inductive coding, followed by axial coding to define the main themes. Quotes to illustrate the results
were selected.
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Missing items in the multi-item domains of the EORTC-QLQ-C30 were imputed with simple
mean imputation, according to the guidelines of the EORTC Quality of Life Group [19]. After the
imputation of these values, an available cases analysis was performed. All other missing data were
assumed to be missing at random, and only available data were analysed. All statistical analyses were
performed using IBM SPSS 25.0 (IBM, Chicago, USA); two-sided p-values of <0.05 were considered
statistically significant.
3. Results
3.1. Participants
We included 1099 of the 1887 invited sarcoma patients (response rate, 58%). The flow-chart and
characteristics of the responders have been published before [9]. Responders were diagnosed at a
mean age of 54.6 years, 54% were male, the mean time since diagnosis was 67.4 months, 76% were
diagnosed with STS, and 47% of the sarcomas were located in the extremities (Table 1).
Table 1. Participant characteristics.
All Patients (n = 1099)
Gender n (%)
Male 595 (54)
Female 504 (46)
Age at diagnosis in years: Mean (SD) 54.6 (15.4)
Socio-economic status n (%)
Low 286 (26.1)
Intermediate 462 (42.1)
High 349 (31.8)
Coping: mean (SD)
Helplessness 8.8 (3.6)
Acceptance 18.8 (4.2)
Disease benefits 15.8 (4.8)
Time since diagnosis in months: Mean (SD) 67.4 (30.4)
Location n (%)
Extremities 514 (47)
Non-extremities 585 (53)
Histology n (%)
Soft tissue sarcoma 835 (76)
Dermatofibrosarcoma protuberans 74 (7)
Liposarcoma 177 (16)
Myxofibrosarcoma 137 (13)
Leiomyosarcoma 113 (10)
Rhabdomyosarcoma 15 (1)
Malignant peripheral nerve sheath tumors (MPNST) 34 (3)
Synovial sarcoma 35 (3)
Vascular sarcoma 43 (4)
Other soft tissue sarcoma 201 (18)
Bone sarcoma 264 (24)
Osteosarcoma 69 (6)
Chondrosarcoma 130 (12)
Chordoma 30 (3)
Ewing sarcoma 28 (3)
Other bone sarcoma 13 (1)
Grade n (%)
Low grade 614 (60)
Intermediate or high grade 407 (40)
Metastases at diagnosis n (%)
Not present 1067 (97)
Present 32 (3)
Treatment modalities n (%)
Surgery 448 (43)
Surgery and radiotherapy 422 (41)
Surgery and chemotherapy 79 (8)
Surgery and radiotherapy and chemotherapy 86 (8)
The n of an individual cell may be smaller due to missing values. Participants who had only undergone radiotherapy,
chemotherapy, or a combination of the two were excluded from this analysis, due to their small group size and
unreliable analysis.
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3.2. Health-Related Quality of Life by Patient and Diagnostic Interval Length
The patient interval lasted ≥1 month in 60% (n = 589). The diagnostic interval lasted ≥1 month in
55% (n = 569). No statistical differences in HRQoL were found for the different patient and diagnostic
interval groups (Figure 1).
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3.4. Independent Association of Patient Interval and Patient and Tumour Characteristics with HRQoL
Global QoL was independently associated with the perceived impact of the diagnostic interval
length on HRQoL (Table 2). Participants perceiving a positive or no impact had a higher global
QoL than those perceiving a negative impact. Furthermore, participants with a lower global QoL
score showed maladaptive coping strategies, with higher scores on helplessness and lower scores on
acceptance and disease benefits. Several tumour characteristics were associated with global QoL.
Table 2. Standardized betas of multivariable linear regression analysis evaluating the association of the
patient interval and other variables with EORTC QLQ-C30 scales.
Global QoL PhysicalFunctioning
Role
Functioning
Emotional
Functioning
Cognitive
Functioning
Social
Functioning
Patient interval
<1 month ref ref ref ref ref ref
≥1 month 0.031 0.017 0.047 –0.032 –0.006 –0.008
Perceived impact of
diagnostic interval
length
–negative ref ref ref ref ref ref
–positive 0.088 ** 0.040 0.044 0.026 0.051 0.027
–no impact 0.065 * 0.032 0.034 0.092 ** 0.044 0.086 **
Gender
–male ref ref ref ref ref ref
–female –0.038 –0.064 * 0.009 –0.039 –0.042 –0.010
Age at diagnosis –0.018 –0.231 ** –0.086 ** 0.174 ** 0.103 ** 0.071 *
Socio–economic status
–low ref ref ref ref ref ref
–intermediate 0.029 0.060* 0.007 0.014 –0.019 0.018
–high 0.034 0.062* 0.029 0.020 0.044 0.038
Coping
–helplessness –0.441 ** –0.601 ** –0.601 ** –0.386 ** –0.323 ** –0.518 **
–acceptance 0.157 ** –0.005 0.063 * 0.239 ** 0.113 ** 0.122 **
–disease benefits 0.118 ** 0.017 0.030 0.010 0.013 0.011
Time since diagnosis –0.036 –0.064 ** –0.035 0.042 0.005 –0.006
Location
–non–extremity ref ref (0.0 ref) ref ref ref
–extremity 0.081 ** –0.060 * 0.037 0.049 0.106 ** 0.045
Histology #
–dermatofibrosarcoma ref ref ref ref ref ref
–liposarcoma –0.103 * 0.041 0.063 0.12 0.061 0.000
–myxofibrosarcoma –0.135 ** 0.013 0.013 –0.025 –0.020 –0.035
–leiomyosarcoma –0.058 0.036 0.087 * –0.026 –0.018 0.040
–rhabdomyosarcoma 0.011 0.011 0.042 0.018 0.031 0.044
–malignant peripheral
nerve sheath tumors
(MPNST)
0.000 –0.065 * –0.005 0.010 0.002 0015
–synovial –0.037 0.015 –0.014 0.013 0.019 0.002
sarcoma
–vascular –0.014 –0.019 –0.001 –0.020 0.023 –0.006
sarcoma
–other STS –0.132 * 0.041 0.049 0.078 0.028 0.034
–osteosarcoma –0.053 –0.098 ** –0.049 0.067 0.026 0.026
–chondrosarcoma –0.075 –0.048 –0.041 0.061 0.010 0.011
–chordoma –0.125 ** –0.102 ** –0.042 –0.008 0.003 –0.046
–Ewing sarcoma –0.012 –0.033 0.010 0.080 * –0.002 0.028
–other BS –0.042 –0.024 0.003 0.007 0.026 0.014
Grade
–low ref ref ref ref ref
–high –0.059 –0.055 –0.044 –0.011 –0.014
Metastases at diagnosis
–not present ref ref ref ref ref ref
–present –0.037 0.027 –0.016 –0.054 –0.038
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Table 2. Cont.
Global QoL PhysicalFunctioning
Role
Functioning
Emotional
Functioning
Cognitive
Functioning
Social
Functioning
Treatment modality
–surgery plus ref ref ref ref ref ref
CHx, RTx, or both
–surgery alone –0.009 –0.002 0.000 0.079 * 0.028
# STS = soft tissue sarcoma; BS = bone sarcoma; CHx = chemotherapy; RTx = radiotherapy. * p < 0.05. ** p < 0.01.
Similar results were found for the functioning scales (Table 2). Coping strategies and especially
the helplessness scale were negatively associated with all the functioning scales. The perceived impact
of the diagnostic interval length on HRQoL showed a similar trend for all the functioning scales but
was only significant for the difference between the no impact group and the negative impact group
on the emotional and social functioning scale. Age was associated with all the functioning scales,
and gender, SES, and time since diagnosis were associated with physical functioning.
3.5. Independent Association of Diagnostic Interval and Patient and Tumour Characteristics with HRQoL
Although diagnostic interval length was not associated with global QoL, the perceived impact of
the diagnostic interval length remained significantly associated (Table 3). Participants perceiving a
positive or no impact had a higher global QoL. Those with maladaptive coping strategies had lower
global QoL scores. Both location and histology were associated with global QoL in the model including
patient interval length.
On the functioning scales, coping strategies, especially the helplessness and acceptance scales,
remained independently associated. The age at diagnosis, gender, SES, and a longer time since
diagnosis remained associated as well.
3.6. Consideration of Patients Who Perceive a Negative Impact of Their Diagnostic Interval Length on HRQoL;
Qualitative Analyses
We identified three main themes: psychological distress, physical inability, and an influence on
prognosis. Of the patients who commented on why their HRQoL was influenced negatively by their
diagnostic interval length (n = 298), 52% said this was due to psychological distress: an increase in
insecurity, fear, and stress. Of these participants, 73% had a diagnostic interval length ≥1 month,
and 39%, ≥3 months. They experienced these emotions not only during the diagnostic trajectory but
also in their current lives. They feared the recurrence of disease, metastases, or death.
• “Fear, you don’t know when and where it recurs. You continuously monitor your body.”
• “Heavy psychological stress during the diagnostic trajectory.”
Many (41%) reported more physical inability due to longer lasting complaints, the growth of the
tumour, and, consequently, more elaborate treatment, such as larger operations and the addition of
radiotherapy or chemotherapy. Of these participants, 81% reported a diagnostic interval ≥1 month,
and 63%, ≥3 months. Some (7%) thought it influenced their prognosis and thought metastases or
disease recurrence could have been avoided with an earlier diagnosis and would have possibly led to
a curative treatment. Of these, 86% experienced a diagnostic interval ≥1 month and 36%, ≥3 months.
• “A lot of pain longer than necessary. Surgical intervention was not possible anymore due to the
long diagnostic trajectory.”
• “Then they would not have to cut it out this far, so I would have fewer complaints now.”
• “Yes, because if there had been an earlier intervention, then the sarcoma would not have been this
large and I would not have had metastases.”
• “Due to not tackling it immediately it came back twice.”
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Table 3. Standardized betas of multivariable linear regression analysis evaluating the association of the
diagnostic interval and other variables with EORTC QLQ-C30 scales.
Global QoL PhysicalFunctioning
Role
Functioning
Emotional
Functioning
Cognitive
Functioning
Social
Functioning
Diagnostic interval
<1 month ref ref ref ref ref ref
≥1 month 0.012 0.016 –0.015 0.019 0.012 –0.027
Perceived impact of
diagnostic interval
length
–negative ref ref ref ref ref ref
–positive 0.087 ** 0.042 0.035 0.034 0.055 0.021
–no impact 0.066 * 0.035 0.027 0.099 ** 0.048 0.079 *
Gender
–male ref ref ref ref ref ref
–female –0.037 –0.064 ** 0.011 –0.041 –0.043 –0.009
Age at diagnosis –0.018 –0.230 ** –0.089 ** 0.177 ** 0.104 ** 0.069 *
Socio–economic status
–low ref ref ref ref ref ref
–intermediate 0.029 0.060 * 0.007 0.015 –0.019 0.018
–high 0.035 0.062 * 0.03 0.019 0.044 0.038
Coping
–helplessness –0.441 ** –0.600 ** –0.604 ** –0.384 ** –0.322 ** –0.520 **
–acceptance 0.157 ** –0.005 0.064 * 0.238 ** 0.113 ** 0.122 **
–disease benefits 0.117 ** 0.017 0.027 0.012 0.014 0.01
Time since diagnosis –0.036 –0.066 ** –0.035 0.042 0.005 –0.007
Location
–non–extremity ref ref ref ref ref ref
–extremity 0.083 ** –0.059 * 0.04 0.046 0.105 ** 0.045
Histology #
–dermatofibrosarcoma ref ref ref ref ref ref
–liposarcoma –0.110 * 0.037 0.054 0.017 0.061 0.003
–myxofibrosarcoma –0.141 ** 0.009 0.005 –0.02 –0.02 –0.032
–leiomyosarcoma –0.062 0.033 0.083 * –0.024 –0.018 0.043
–rhabdomyosarcoma 0.008 0.009 0.038 0.021 0.031 0.045
–malignant peripheral
nerve sheath tumors
(MPNST)
–0.003 –0.067* –0.007 0.01 0.002 0.017
–synovial –0.039 0.013 –0.012 0.011 0.017 0.005
sarcoma
–vascular –0.018 –0.022 –0.006 –0.017 0.023 –0.004
sarcoma
–other STS –0.139 ** 0.037 0.04 0.084 0.029 0.038
–osteosarcoma –0.055 –0.100 ** –0.051 0.068 0.026 0.028
–chondrosarcoma –0.079 –0.051 –0.042 0.061 0.009 0.015
–chordoma –0.127 ** –0.103 ** –0.042 –0.008 0.003 –0.044
–Ewing sarcoma –0.013 –0.034 0.008 0.081 * –0.001 0.029
–other BS –0.044 –0.025 –0.001 0.009 0.026 0.014
Grade
–low ref ref ref ref ref ref
–high –0.058 –0.054 –0.011 –0.044 –0.01 –0.015
Metastases at diagnosis
–not present ref ref ref ref ref ref
–present –0.037 0.027 0.005 –0.017 –0.054 –0.037
Treatment modality
–surgery plus ref ref ref ref ref ref
CHx, RTx, or both
–surgery alone –0.006 –0.001 0.037 –0.003 0.078 * 0.028
# STS = soft tissue sarcoma; BS = bone sarcoma; CHx = chemotherapy; RTx = radiotherapy. * p < 0.05. ** p < 0.01.
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4. Discussion
In this cross-sectional cohort study among a large sarcoma survivorship population, we found
that patient and diagnostic interval length were not associated with HRQoL scores, but the perceived
impact of the diagnostic interval length on HRQoL was associated with HRQoL scores.
There have been no published studies looking at the effect of patient and diagnostic interval
length on HRQoL among cancer survivors. However, in a systematic review about the effect of total
interval length on the outcomes for symptomatic cancer just after diagnosis, Neal et al. found that an
earlier diagnosis of cancer will likely improve HRQoL [5].
Although patient and diagnostic interval length were not associated with HRQoL scores, we found
the perceived impact of the diagnostic interval length on HRQoL to be independently associated with
global QoL and several HRQoL functioning scales. Participants perceiving a negative impact had
lower HRQoL scores than those perceiving a positive or no impact. Furthermore, participants with
lower HRQoL scores used maladaptive coping strategies. Participants perceiving a negative impact
of their diagnostic interval on their HRQoL showed higher scores on the subscale helplessness and
lower scores on the acceptance and disease benefits scales. Both the perceived impact and coping
remained independently associated in our multivariable model. The question remains why perceived
impact remains associated; this may be due to the actual time to diagnosis, or other patient or tumour
characteristics. The coping strategy was also found to be a significant predictor of HRQoL among
other malignancies [25–27]. The use of coping strategies can vary between patients and over time or
between situations [23]. Although probably not sarcoma specific and solely related to the diagnostic
interval length, our results indicate that supportive services focusing on developing adaptive coping
strategies may positively influence patients’ HRQoL.
Our finding that the perceived impact of the diagnostic interval length on HRQoL is associated
with HRQoL scores is further supported by the qualitative analysis of the open text field answers,
in which many patients perceiving a negative impact describe psychological distress, more physical
disabilities, and a worse prognosis due to their diagnostic interval length. Although their perception of
the influence of the relationship between prognosis and diagnostic interval length may not be entirely
supported by current literature [6], it is worrying that 2–10 years after diagnosis, patients still report
this psychological and physical burden. We are not aware of previous studies examining patients’
perception of diagnostic interval length and HRQoL. However, our findings are supported by two
British and two Danish studies, which reported that cancer patients diagnosed through fast-track
referrals were less likely to be dissatisfied with the length of waiting times and more likely to be
satisfied with their subsequent cancer care than those referred electively [28–31].
To our knowledge, this is the only study that has investigated the influence of patient and
diagnostic interval length and the perceived impact of the diagnostic interval length on HRQoL among
adult sarcoma survivors. The overall completeness of the variables in our analysis sample was high.
Our study has several limitations. First, although we invited all patients diagnosed with sarcoma
in the Netherlands between 2008 and 2016, there was a selection bias with a probable overrepresentation
of patients with high health literacy. Furthermore, due to the survivorship nature of the study, there is a
natural selection of patients with favourable prognoses, less aggressive histological subtypes, and low
co-morbidity. The longitudinal assessment, preferably in daily clinical practice, of HRQoL, starting from
diagnosis throughout the disease continuum, will provide more comprehensive data to determine
causal associations and will be less prone to recall bias. We have set up a prospective study in which
newly diagnosed sarcoma patients are asked to complete questionnaires for a period of two years
(QUEST study; ClinicalTrials.gov Identifier: NCT03441906) to overcome this limitation. Second,
our interval length data are subject to recall bias. However, 90% and 95% of the patients indicated they
still remembered their patient and diagnostic interval lengths. In general, significant events, such as
cancer diagnosis, are not likely to be forgotten [32]. Furthermore, the estimation of the duration of
an event is extremely stable [33]. Third, one may argue that a cut-off of 1 month for the diagnostic
interval length for sarcomas is too short. However, a sensitivity analyses with a cut-off of 3 months
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did not show different results. Last, one of the biggest challenges when measuring patient-reported
outcomes is determining what instrument assesses HRQoL or other relevant topics best among the
study population. Given the qualitative results in our data, the EORT-QLQ-C30 may be too generic to
measure the impact of the total interval length on the HRQoL of sarcoma survivors. In future research,
patient-reported outcome measures focusing on disability, distress, or recurrence may better capture
this relationship.
Our study has resulted in more understanding of the survivorship experience. The perceived
impact of the diagnostic interval and coping strategies have a long-lasting effect on global HRQoL
and all the functional scales; it thus seems important to keep the diagnostic trajectory and perception
thereof as short as possible. Strategies could include creating awareness among the general population
and healthcare providers about sarcoma, reference networks, and centres of expertise, with rapid
diagnostic pathways at sarcoma centres.
Since the perceived effect of diagnostic interval length still causes physical and psychological
disabilities amongst patients 2–10 years after diagnosis, the improvement of services, treatment,
and rehabilitation programs may contribute to improving the HRQoL of sarcoma patients. Patients with
maladaptive coping strategies are at risk of lower HRQoL. Sarcoma care could be improved if healthcare
providers acknowledge patients’ frustrations regarding their diagnostic pathway and have an eye for
their coping strategies. If necessary, supportive care focusing on coping strategies could be given early
in the treatment pathway. This will improve HRQoL and may lead to more personalized rehabilitation
services, probably resulting in the restoration of social and employment activities and thus having a
positive economic impact.
5. Conclusions
The perceived impact of the diagnostic interval length was associated with the HRQoL of sarcoma
survivors, whereas the actual length was not associated with HRQoL. Maladaptive coping strategies
were independently associated with HRQoL. The sarcoma diagnostic pathway should be kept short in
order to provide the best treatment possible and optimize HRQoL.
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